JP2023539476A5 - - Google Patents

Info

Publication number
JP2023539476A5
JP2023539476A5 JP2023512755A JP2023512755A JP2023539476A5 JP 2023539476 A5 JP2023539476 A5 JP 2023539476A5 JP 2023512755 A JP2023512755 A JP 2023512755A JP 2023512755 A JP2023512755 A JP 2023512755A JP 2023539476 A5 JP2023539476 A5 JP 2023539476A5
Authority
JP
Japan
Prior art keywords
annexin
liquid pharmaceutical
sequence
pharmaceutical preparation
terminal peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539476A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/073186 external-priority patent/WO2022038281A1/en
Publication of JP2023539476A publication Critical patent/JP2023539476A/ja
Publication of JP2023539476A5 publication Critical patent/JP2023539476A5/ja
Pending legal-status Critical Current

Links

JP2023512755A 2020-08-21 2021-08-20 アネキシンa1のn末端ペプチド製剤及び方法 Pending JP2023539476A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20192142 2020-08-21
EP20192142.6 2020-08-21
PCT/EP2021/073186 WO2022038281A1 (en) 2020-08-21 2021-08-20 Annexin a1 n-terminal peptide formulations and methods

Publications (2)

Publication Number Publication Date
JP2023539476A JP2023539476A (ja) 2023-09-14
JP2023539476A5 true JP2023539476A5 (enExample) 2024-08-27

Family

ID=72193322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512755A Pending JP2023539476A (ja) 2020-08-21 2021-08-20 アネキシンa1のn末端ペプチド製剤及び方法

Country Status (10)

Country Link
US (2) US20240041977A1 (enExample)
EP (3) EP4200320A1 (enExample)
JP (1) JP2023539476A (enExample)
CN (1) CN116323649A (enExample)
AU (1) AU2021327733A1 (enExample)
CA (1) CA3192030A1 (enExample)
ES (1) ES3031633T3 (enExample)
HU (1) HUE071875T2 (enExample)
PL (1) PL4200319T3 (enExample)
WO (2) WO2022038281A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4200319T3 (pl) * 2020-08-21 2025-08-18 Resother Pharma A/S Preparaty peptydu n-końcowego aneksyny a1 i sposoby
US20250345392A1 (en) 2022-06-30 2025-11-13 Resother Pharma A/S Annexin a1 liquid pharmaceutical composition
AU2024234229A1 (en) 2023-03-13 2025-09-25 Resother Pharma A/S Annexin a1 administration regime
EP4680262A1 (en) 2023-03-13 2026-01-21 Resother Pharma A/S Annexin a1 delayed dosing
WO2025083393A1 (en) 2023-10-16 2025-04-24 Therakind Limited Antimicrobial use of peptides derived from annexin a1
WO2025083394A1 (en) 2023-10-16 2025-04-24 Therakind Limited Antimicrobial use of annexin a1 protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
US9102753B2 (en) 2011-06-15 2015-08-11 Ugp Therapeutics, Inc. Anti-inflammatory pharmaceutical products
ES2700933T3 (es) * 2011-10-14 2019-02-20 Baxalta GmbH Purificación de proteínas mediante cromatografía de intercambio aniónico
JP2017513875A (ja) 2014-04-22 2017-06-01 ティーエックスピー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 分枝状アミノ酸プローブを有するペプチド類似体
CN110302176A (zh) * 2019-06-25 2019-10-08 中国人民解放军陆军军医大学 一种抗炎多肽纳米药物及制备方法
PL4200319T3 (pl) * 2020-08-21 2025-08-18 Resother Pharma A/S Preparaty peptydu n-końcowego aneksyny a1 i sposoby
US20250345392A1 (en) * 2022-06-30 2025-11-13 Resother Pharma A/S Annexin a1 liquid pharmaceutical composition

Similar Documents

Publication Publication Date Title
JP2023539476A5 (enExample)
US6616931B1 (en) Rotavirus vaccine formulations
RU2011127913A (ru) Составы, содержащие антитела
CN102712677B (zh) 脂肽组合物和相关方法
JP4902103B2 (ja) 凍結乾燥フォームによる生物活性材料の保存
CA2272245A1 (en) Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies
US5932223A (en) Rotavirus vaccine formulations
US6403098B1 (en) Rotavirus vaccine formulations
US8216588B2 (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
RU2014151424A (ru) Термостабильные составы вакцины
EP0939648B1 (en) Rotavirus vaccine formulations
JP2010528003A (ja) 凍結乾燥フォームによる生物活性材料の防腐
WO2010146598A2 (en) Stable, dried rotavirus vaccine, compositions and process for preparation thereof
JPH01279843A (ja) 凍結乾燥a型肝炎ワクチン
JP2022553058A5 (enExample)
TW202330924A (zh) 新型冠狀病毒mRNA疫苗及其製備方法與用途
EP2853270B1 (en) Recombinant avian-infectious coryza vaccine and process for preparing same
US9999663B2 (en) Immunogenic formulation containing recombinant live BCG that express antigens of metapneumovirus (hMPV), in a suspension prepared from a lyophilisate, without requiring an adjuvant, suitable for pharmaceutical use
JP2023538669A5 (enExample)
JP2023526218A5 (enExample)
EP0560969B1 (fr) Vaccin comprenant une sous-unité du récepteur de la transferrine humaine tel qu'isolé de Neisseria meningitidis
JP2024521329A5 (enExample)
RU2024121592A (ru) Лиофилизированная композиция, содержащая слитый белок, включающий α-галактозидазу А
AU2008202660B2 (en) Rotavirus vaccine formulations
US20230045642A1 (en) S. aureus antigens and compositions thereof